Lotteau
Vincent Lotteau, Vourles FR
Patent application number | Description | Published |
---|---|---|
20110091994 | Methods for Screening Compounds for Treating and/or Preventing an Hepatitis C Virus Infection - The present invention relates to methods for screening compounds for treating and/or preventing an Hepatitis C Virus (HCV) infection. | 04-21-2011 |
20110135684 | Use of L-alpha-lysophosphatidylcholine to obtain the differentiation of monocytes in mature dendritic cells in vitro - A method for treating and/or preventing certain ailments by administering to a person in need thereof L-α-lysophosphatidylcholine as an agent for activating the immune system of the person. Also, vaccine compositions that include L-α-lysophosphatidylcholine. | 06-09-2011 |
Vincent Lotteau, Lyon Cedex 07 FR
Patent application number | Description | Published |
---|---|---|
20100172870 | METHODS, USES AND COMPOSITIONS FOR MODULATING REPLICATION OF HCV THROUGH THE FARNESOID X RECEPTOR (FXR) ACTIVATION OR INHIBITION - Uses, methods and compositions for modulating replication of viruses of the Flaviviridae family, such as hepatitis C virus, through the farnesoid X receptor (FXR) activation or inhibition. More specifically, the use of an antagonist of FXR or an inhibitor of expression thereof for the manufacture of a medicament intended for treating a Flaviviridae virus infection in a subject in need thereof. The use of antagonists of FXR, such as guggulsterone, or use of inhibitors of FXR expression. A cell culture system allowing the replication of HCV and to methods for diagnosing HCV infection, screening of anti-viral compounds and vaccine or viral protein production. | 07-08-2010 |
20120322147 | DIRECT PROTEIN DELIVERY WITH ENGINEERED MICROVESICLES - The present invention relates to direct protein delivery with engineered micro vesicles. | 12-20-2012 |
Vincent Lotteau, Lyon Cedex FR
Patent application number | Description | Published |
---|---|---|
20130034900 | REPROGRAMMATION OF EUKARYOTIC CELLS WITH ENGINEERED MICROVESICLES - The present invention relates to a non-genetic, detergent-free, bacteria-free method for reprogramming a eukaryotic cell, in particular for obtaining induced pluripotent stem cells (iPS), by using engineered microvesicles carrying at least one reprogramming transcription factor, wherein said engineered microvesicles are virus-free. | 02-07-2013 |
20140242107 | Direct Protein Delivery with Engineered Microvesicles - The present invention relates to direct protein delivery with engineered micro vesicles. | 08-28-2014 |
20140356943 | Reprogrammation of Eukaryotic Cells with Engineered Microvesicles - The present invention relates to a non-genetic, detergent-free, bacteria-free method for reprogramming a eukaryotic cell, in particular for obtaining induced pluripotent stem cells (iPS), by using engineered microvesicles carrying at least one reprogramming transcription factor, wherein said engineered microvesicles are virus-free. | 12-04-2014 |
Vincent Lotteau, Lyon FR
Patent application number | Description | Published |
---|---|---|
20140024101 | METHOD FOR INCREASING THE REPLICATION CAPACITY OF AN INFLUENZA VIRUS IN CULTURED CELLS - The present invention relates to methods for increasing the replication capacity of an influenza virus in cultured cells. More particularly, the present invention relates to a method for increasing the replication capacity of an influenza virus in a cell comprising the steps consisting of i) infecting said cell with said influenza virus and ii) culturing said infected cell with a least one molecule selected from the group consisting of Dibucaine, Aprindine, Amiloride, Mevinolin, Simvastatin, Promathazine, Pranlukast, Nimodipine, Ibutilide hemifumarate Salt, Risperidone and derivatives or analogues thereof. | 01-23-2014 |
20140030224 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING INFLUENZA VIRUSES REPLICATION - The present invention relates to methods and pharmaceutical compositions for inhibiting influenza virus replication. More particularly, the present invention relates to a compound selected from the group consisting of Gemcitabine, Obatoclax Mesylate, Docetaxel, HA-14, Alsterpaullone, GSK3B inhibitor VIII, GSK3B inhibitor XV, Indirubin 3′- monoxime, L glutathione reduced, Fluocinolone acetonide, Tirofiban, Topotecan hydrochloride, Clofarabine, Vinblastine, Menadione Crystalline and derivatives or analogues thereof for use in the treatment of an influenza infection in a subject in need thereof. | 01-30-2014 |
20140296106 | METHODS FOR SCREENING SUBSTANCES CAPABLE OF MODULATING THE REPLICATION OF AN INFLUENZA VIRUS - The present invention relates to methods for screening substances capable of modulating the replication of an influenza virus. More particularly, the present invention relates to methods for screening a plurality of substances capable of modulating the replication of an influenza virus in a host cell comprising the step consisting of identifying a substance that modulates the specific interaction of a host cell protein with a viral protein required for viral replication as depicted in table 1 or identifying a substance that modulates the specific interaction of a first host cell protein as depicted in table 1 with a second host cell protein present in cellular network of the first host cell protein or identifying a substance that modulates the expression of a host cell protein as depicted in table 1, or identifying a substance that modulates the activity of a host cell protein as depicted in table 1 | 10-02-2014 |